Minkowski Prize 2006

Members of EASD are invited to submit nominations for the 2006 Minkowski Prize, which since 1966 has been generously sponsored by Sanofi-Aventis. The prize consists of a Certificate and Euro 20,000 (twenty thousand) plus travel expenses. The candidate must be less than 40 years of age on 1 January 2006. A non-successful application may be carried forward at the request of the applicant. Self-nomination is possible.

The prize will be given in relation to research, which has been carried out by a person normally resident in Europe. It is awarded for distinction manifested by publications, which contribute to the advancement of knowledge concerning diabetes mellitus.

Nominations or re-nominations should be in the form of **six copies** of the candidate's curriculum vitae, including a complete bibliography, **six copies** each of the most relevant publications (not more than ten), and six copies of a statement in English by the proposer(s) explaining the manner in which the candidate's published contributions have aided knowledge concerning diabetes mellitus. Such a statement should not exceed 1,000 words. Additional letters of support will be disregarded.

Nominations or re-nominations should be sent to the

EASD Secretariat
Rheindorfer Weg 3
D-40591 Düsseldorf
Germany

to arrive not later than **15 February 2006**.

The recipient of the Prize is expected to give the 41st Minkowski Lecture describing his/her most important scientific achievements during the EASD Annual Meeting, which will be held in Copenhagen/Malmö, Denmark/Sweden, 14-17 September 2006, and is expected to write a respective review article for publication in *Diabetologia*.

Claude Bernard Lecturer 2007

Members of EASD are invited to submit nominations for the 2007 Claude Bernard Lecturer. The EASD is very grateful to Sanofi-Aventis (France) for their continuous support of this award. The Lecture will be delivered during the 43rd EASD Annual Meeting to be held in Amsterdam, The Netherlands, 17-21 September 2007.

There are no restrictions regarding the age of the candidate who may come from any part of the world. The aim of the Lectureship is to recognise an individual's innovative leadership and outstanding contributions to the advancement of knowledge in the field of diabetes mellitus and related metabolic diseases.

Nominations or re-nominations should be in the form of a letter of recommendation of not more than 1,000 words and should include the curriculum vitae of the nominee and a list of not more than ten relevant publications.

Six copies of each should be sent to the

EASD Secretariat
Rheindorfer Weg 3
D-40591 Düsseldorf
Germany

to arrive not later than **15 April 2006**.

In addition, one copy of a full bibliography of the candidate should be provided.

Castelli Pedroli Prize 2006

Members of the EASD are invited to submit nominations for the 2006 Castelli Pedroli Prize. The prize consists of an award of Euro 8,000 (eight thousand), presented by the family of the late Maria Carla Castelli Pedroli.

The prize is awarded for outstanding contributions in the field of the histopathology, pathogenesis, prevention and treatment of the complications of diabetes mellitus, which have been carried out in Europe by a member of the EASD normally resident in Europe. The recipient should have a distinguished track record of research in the field. Publications in internationally recognised scientific journals over the last 5 years should demonstrate continuing activity, originality and excellence in the field.

Nominations or re-nominations may be submitted by any member of the EASD, and should comprise of **six copies** of each of the following:

- a) Curriculum vitae of the candidate
- b) Letter of recommendation
- c) Re-prints of the eight most important publications emphasising recent contributions.

Nominations or re-nominations should be sent to the

EASD Secretariat
Rheindorfer Weg 3
D-40591 Düsseldorf
Germany

to arrive not later than **15 February 2006**.

The recipient of the prize will be required to deliver a lecture named in honour of Camillo Golgi during the 42nd Annual Meeting of EASD, to be held in Copenhagen/Malmö, Denmark/Sweden, 14-17 September 2006.

Council Membership Nominations 2007 - 2010

Dear Member,

The EASD invites nominations for council membership for the period September 2007 – September 2010. The nominations will be considered by the members of the Executive Committee and Council of EASD.

The nominee should be a paid-up member of the Association. Nominations must include a letter of recommendation, signed by three EASD members and should be sent to the

EASD Secretariat
Rheindorfer Weg 3
D-40591 Düsseldorf
Germany

to arrive not later than **1 March 2006**.

**European Foundation for the Study of Diabetes (EFSD)
and
Medtronic Europe S.A.**

**Clinical Research Grant
The Usefulness of CSII in Microalbuminuric Type 1 Diabetic Patients**

Request for Applications

**EFSD and Medtronic
announce
1 Grant of Euro 150,000 over 3 years**

Background

The earliest clinical manifestation of diabetic nephropathy is microalbuminuria. In people with type 1 diabetes, microalbuminuria can progress to overt nephropathy and even to end-stage renal disease. Hyperglycaemia has been shown to be a very important factor associated with the degree of glomerulopathy in incipient nephropathy, and improved metabolic control has been shown to arrest, and even reverse, glomerular changes.

The Diabetes Control and Complications Trial (DCCT) reported that intensive insulin treatment of type 1 diabetes led to a striking reduction in the development and progression of microvascular complications. Continuous subcutaneous insulin infusion (CSII) offers the most physiologic mode of insulin delivery available, and continuous glucose monitoring has been shown to benefit both paediatric and adult type 1 diabetic patients by providing accurate data on 24-hour blood glucose profiles.

Emphasis of Research Project

The research project will test the usefulness of CSII in microalbuminuric type 1 diabetic patients and, in particular, investigate if realtime glucose sensing could further benefit this patient population by reducing post-prandial hyperglycaemia.

Funding

Research will be supported through the award of a fixed sum grant of Euro 50,000 per annum for three

consecutive years. Total funding will therefore amount to Euro 150,000. All budgets are to be prepared in Euro.

Mechanism of Support and Review

Applications for this EFSD/Medtronic Clinical Research Grant are invited from single non-profit institutions or groups of such institutions from Europe or associated countries. The principal investigator and any co-investigators must be normally employed at a non-profit institution and the study must be performed at such a place of work.

Applications will be subject to scientific review by a specialised ad hoc committee. It is anticipated that applications will be received, reviewed and the successful project approved for funding by June 2006.

Prior to any final decision on funding, and in order to offer applicants the opportunity to benefit from the review process, EFSD reserves the right to request revision to applications in accordance with the recommendations of the review committee.

Application forms may be requested from:

Foundation@easd.org

All applications must be prepared on the official forms and completed in strict accordance with the detailed instructions to be found on these forms. In particular, applicants are reminded that any pages in addition to the maximum of 10 allowed for the scientific section of the application will be deleted prior to review. Additional

material (in the form of an appendix, attachment, reprints, etc.) is not permitted and will not be sent to reviewers.

Applications should be submitted by post no later than 30 March 2006 (date of receipt) to:

Viktor Jörgens,
Executive Director
European Foundation for the Study of Diabetes
Rheindorfer Weg 3
D-40591 Düsseldorf, Germany
Tel: +49-211-758469-0
Fax: +49-211-758469-29
e-mail: Foundation@easd.org

Review Considerations

Completed applications will be evaluated in accordance with the criteria stated below for scientific/technical merit by an appropriate scientific committee convened by EFSD and Medtronic.

Review criteria are as follows:

- **Significance:** Is the study relevant to the programme? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of the proposed studies on the concepts or methods that drive this field?
- **Approach:** Are the conceptual framework, design, methods and analyses adequately developed, well integrated, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics?

- **Innovation:** Does the project employ novel concepts, approaches or methods? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies?
- **Investigator:** Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)?
- **Environment:** Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support?
- **Relevance:** A brief statement of the impact of the proposed study on diabetes research within the framework of the Programme's plan and objectives. **Reporting Requirements** The principal investigator funded by this grant is required to submit a scientific report at the end of the funding period. Support by the EFSD/Medtronic Clinical Research Grant must be acknowledged in all publications and communications.

Schedule

Announcement: December 2005
Application Deadline: 30 March 2006
Anticipated Award: June 2006

EFSD/Eli Lilly Research Fellowships

Euro 100,000 for two fellowships of Euro 50,000 each

The objective of the EFSD/Eli Lilly Research Fellowships is to encourage research in the fields of metabolism and complications of diabetes and to promote excellence in medical education. Applicants should have demonstrated their ability in the field of diabetes research.

Two fellowships will be awarded annually in the sum of Euro 50,000 (fifty thousand); the money awarded will be paid into the account of the host institution.

The following regulations shall apply:

Application may be made by any paid-up member of EASD under the age of 40 years on 1 January in the year of the award. The application shall consist of:

1. Full name, address, date of birth and brief curriculum vitae of the applicant.
2. Proof of current EASD Membership.
3. List of publications by applicant as first or co-author.
4. Date and nature of appointment held by applicant, with brief resumé of work on which currently employed.
5. A report (not more than 2-3 pages) providing full details of the project for which the fellowship is required. This should cover the aims, background, methodology and hoped-for results of the project.
6. Letter of commitment from the host institution.

Six copies of the application should be sent to:

European Foundation for the Study of Diabetes
Rheindorfer Weg 3
D-40591 Düsseldorf
Germany

to arrive not later than **15 February 2006**.

The EFSD/Eli Lilly Fellowships will be announced annually by the President of EASD during the General Assembly of the Association.

Upon completion of the fellowships, the recipients will be invited to present their research results at a scientific meeting held at Eli Lilly and Company.

Albert Renold Fellowships for Young Scientists

The Albert Renold Fellowships for Young Scientists will enable young scientists to travel and stay at other laboratories in order to learn different scientific techniques. The Fellowships are named after Albert Renold, the founding father of EASD. The duration of the stay should not exceed 3 months. A maximum of twelve Fellowships can be awarded every year. Each award will be for up to Euro **6,000 (six thousand)**. The EFSD Albert Renold Fellowship programme is supported by an unrestricted educational grant from Merck Sharp and Dohme (MSD).

The following regulations will apply:

Applications may be made by any paid-up member of EASD under the age of 35 years (PhD) or 40 years (MD/PhD with clinical training) on 1 January in the year of the award. The application should include:

- a. Full name, address, date of birth and brief curriculum vitae of the applicant
- b. Proof of current EASD Membership
- c. Statement of how the visit will benefit the applicant and his/her department (1 side A4 maximum)
- d. Date and nature of present appointment held by applicant
- e. Letter of recommendation by the Head of the Department
- f. Letter from the host institution describing the objectives of the stay
- g. Budget details

Three copies of the application should be sent to:

European Foundation for the Study of Diabetes
Rheindorfer Weg 3
D-40591 Düsseldorf
Germany

These Fellowships are available throughout the whole year. There is no deadline for submission.

EFSD/AstraZeneca Clinical Travel Fellowships

Clinical Travel Fellowships: The EFSD/AstraZeneca Clinical Travel Fellowships will enable young clinicians from Europe and associated states to travel to and stay at other laboratories in order to learn new clinical skills or techniques in clinical diabetes research. The duration of the stay should be suited to the training purpose and must not exceed two months. Each Fellowship will be in the amount of up to Euro 5,000 (five thousand) dependent on the length of stay, local costs and costs of travel. This money will be paid into the account of the home institution where the Fellow is normally employed.

Defrayment of costs at host institution: An additional Euro 1,000 (one thousand) will be made available to the host institution to defray costs of training (to include supplies, sample analysis, access to specialised equipment, etc). This sum will be paid into the account of the host institution where the work will be performed.

Supplementary Transfer of Technology Award: Under special circumstances, at the specifically justified request of the home institution, an additional sum of up to Euro 10,000 (ten thousand) may be awarded to facilitate transfer to the home institution by the Fellow of the newly acquired skills/technique. Examples might include costs of setting up the new technique or purchasing/upgrading equipment related to that technique. The money awarded will be paid into the account of the home institution where the work will be performed by the Fellow on his/her return.

An initial total sum of Euro 50,000 (fifty thousand) has been made available to this Fellowship scheme. The number of Fellowships awarded will be dependent on their individual cost and the combined costs of any Supplementary Transfer of Technology Awards.

Please note: No overheads will be payable to either the host or the home institution on this Fellowship Award.

The following regulations will apply:

Applications may be made by any paid-up member of EASD under the age of 40 years on 1 January in the year of the Award. The applicant must be a clinician in an

institution with an active clinical research programme. The application should include:

1. Full name, address, date of birth and brief curriculum vitae of the applicant (with list of publications).
2. Proof of current EASD Membership.
3. Statement of how the visit will benefit the applicant and his/her home department (1 side A4 maximum).
4. Date and nature of present appointment held by the applicant.
5. Letter of recommendation by the Head of the home department including a brief explanation of how the Fellow will use the new skills/techniques after returning to the home institution (1 side A4 maximum).
6. Letter from the host institution (where the visit will be made) describing the training objectives and how the Euro 1,000 costs award will be spent (1 side A4 maximum).
7. Budget details to include: costs of cheapest return travel between home and host institution; duration of stay and estimated living expenses (room, food, local transport).

Supplementary Transfer of Technology Award:

Note: Application for a supplementary award must be in combination with that for a Clinical Travel Fellowship. Supplementary awards will only be made under exceptional circumstances: the Review Committee will be looking for clear justification of the special needs/financial hardship of the home institution that would otherwise prevent transfer of the newly acquired technology by the Fellow to this institution.

The application should include the following documents signed jointly by the Fellow and Head of the home department:

1. List of current institutional and non-institutional clinical research support, and an explanation of why it will not be possible, from these or other funds, to cover the costs of introduction of the newly acquired skills/techniques by the Fellow upon his/her return to the home institution.
2. Confirmation that in the event of this award being made, the Fellow, having received training, will be

responsible for introduction of the newly learned skills/techniques at the home institution as part of his/her normal employment.

3. Budget (with justification) of the proposed use of funds, not to exceed Euro 10,000 (ten thousand).

Three copies of the application should be sent to:

European Foundation for the Study of Diabetes
Rheindorfer Weg 3
D-40591 Düsseldorf
Germany

These Fellowships are available throughout the whole year. There is no deadline for submission and applicants may expect a decision within 3 weeks.

Awards will be announced by the President of EASD during the Annual Meeting of EASD.

Other Announcements

G.B. Morgagni Prizes 2006

The “G.B. Morgagni Prizes” are awarded under the auspices of the School of Medicine of the University of Padua and supported by an unrestricted educational grant from the Servier Research Group.

The prizes, consisting of one Morgagni Medal (gold medal and 20,000 Euros) and two Young Investigator Awards (silver medal and 8,000 Euros), are conferred every two years for outstanding achievements in the field of metabolism.

Nominations are now open for the Morgagni Medal which will be awarded to a distinguished European scientist actively involved in original and innovative investigations in the field of diabetes and its complications.

Each candidate for the Gold Medal should be nominated by at least two individuals who should provide the nominee’s curriculum vitae and supporting statements of not more than 500 words.

Applications are also invited from young European scientists (not yet 40 on 1 January 2006) who should forward a brief letter of application, curriculum vitae, list of publications and reprints of their five most important manuscripts.

The G.B. Morgagni Prizes will be presented during the Ninth European Symposium on Metabolism which will be held in Padua (Italy) from 12-14 October, 2006. The winner of the Morgagni Medal will present a lecture during the Awards Ceremony.

Nominations for the G.B. Morgagni Medal and applications for the Young Investigator Awards must reach our offices by 1 February 2006. Documents may be forwarded by surface mail to the address below or by e-mail (saved in RTF). Reprints should be sent only by post.

Prof. Gaetano Crepaldi
The G.B. Morgagni Prizes Committee
Centro Studio per
l’Invecchiamento – C.N.R.
Via Giustiniani 2
I-35128 Padova
Italy
E-mail: crepaldi.metabolism@unipd.it

European Association for the Study of Diabetes

EASD Executive Committee

President:	E. Ferrannini, Pisa (retires 2007)
Vice-President:	U. Smith, Göteborg (retires 2008)
Vice-President:	E. Standl, Munich (retires 2006)
Honorary Secretary:	D. L. Eizirik, Brussels (retires 2007)
Honorary Treasurer:	J. Škrha, Prague (retires 2006)
Chairman of the Postgraduate Education Sub-Committee:	T. Pieber, Austria (retires 2008)
Editor-in-Chief, DIABETOLOGIA:	E. Gale, Bristol (retires 2007)

EASD Council comprises of the Officers above and the following members:

Term Expiring September 2006	Term Expiring September 2007	Term Expiring September 2008
I. Gourieva, Moscow	L. Czupryniak, Lodz	K. Dahl Jørgensen, Oslo
S. Lenzen, Hanover	L. Gardete Correia, Lisbon	R. Heine, Amsterdam
C. Sanjeevi, Stockholm	D. Mauricio, Barcelona	B. Mankovsky, Kiev
J.-L. Selam, Tustin	T. Otonkoski, Helsinki	S. Sasson, Jerusalem

The Past President, P.A. Halban, and the Secretary of the Postgraduate Education Sub-Committee, N.D. Hancu, are members of the Council ex officio.

HONORARY AUDITORS

N. Katsilambros, Athens and M. Tiedge, Rostock

HONORARY MEMBERS

G. Alberti, Newcastle – D. Andreani, Rome – W. Creutzfeldt, Göttingen – A. Czyzyk, Warsaw – J.K. Davidson, Atlanta – T. Deckert, Hellerup – P. Freychet, Nice – L.G. Heding, Copenhagen – C. Hellerström, Uppsala – H. Keen, London – E. Kohner, London – P. Lefèbvre, Liège – R. Luft, Stockholm – C. Lurie, New York – J. Pirart, Brussels – S. Rahbar, Duarte – P. Randle, Oxford – E. Shafir, Jerusalem – D. Steiner, Chicago – E. von Wasielowski, Munich

GOLD MEMBERS

Astra Zeneca, Macclesfield, UK – Eli Lilly & Co., Indiana, USA – GlaxoSmithKline, Middlesex, UK – LifeScan, Inc., California, USA – Merck & Co. Inc., New Jersey, USA – Novartis Pharma AG, Basel, Switzerland – Novo Nordisk A/S, Bagsvaerd, Denmark – Pfizer, Inc, New York, USA – Sanofi-Aventis, Paris, France – Servier, Neuilly-sur-Seine, France – Takeda Chemical Industries Ltd., Osaka, Japan

SILVER MEMBERS

Abbott Laboratories GmbH, Wiesbaden, Germany – Bayer HealthCare, Leverkusen, Germany – Johnson & Johnson, New Jersey, USA – Merck KGaA, Darmstadt, Germany – Sankyo Pharma GmbH, Munich, Germany – Sooil Development Co., Ltd., Seoul, Korea

ASSOCIATE MEMBERS

Amylin Europe Ltd., Oxford, UK – Animas Corporation, Pennsylvania, USA – A. Menarini Diagnostics, Grassano, Italy – Becton Dickinson Consumer Healthcare Europe, Pont-de-Claix, France – Berlin Chemie AG, Berlin, Germany – Boehringer Ingelheim GmbH, Ingelheim, Germany – HemoCue AB, Angelholm, Sweden – Medtronic Europe, Brussels, Belgium – Nipro Diabetes Systems, Florida, USA – Owen Mumford Ltd., Oxford, UK – Roche Diagnostics GmbH, Mannheim, Germany – Smiths Medical MD, Inc., Minnesota, USA – Ypsomed GmbH, Sulzbach, Germany

The EASD Executive Committee is also the Executive Committee of the European Foundation for the Study of Diabetes (EFSD)

EASD Secretariat:

Executive Director: V. Jörgens
M. Grüßer, M. Hata,
A. Klee, G. Luetkemeier, P. Nani,
K. Page, C. Persidis, R. Sautter
EURADIA: C. Brendel
EFSD: S. Burgess

Office:

Rheindorfer Weg 3
D-40591 Düsseldorf, Germany
Tel: +49-211-758469-0
Fax: +49-211-758469-29
secretariat@easd.org
www.easd.org

FUTURE MEETINGS

14-17 September 2006: Copenhagen/Malmö; September 2007: Amsterdam;